Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 6/20 | 0.56 |
| ▸ | PSEN2 | P49810 | 6/20 | 0.56 |
| ▸ | APH1B | Q8WW43 | 6/20 | 0.56 |
| ▸ | NCSTN | Q92542 | 6/20 | 0.56 |
| ▸ | APH1A | Q96BI3 | 6/20 | 0.56 |
| ▸ | PSENEN | Q9NZ42 | 6/20 | 0.56 |
| ▸ | CNR2 | P34972 | 5/20 | 0.55 |
| ▸ | CNR1 | P21554 | 4/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | CRHBP | P24387 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20733374 | 0.81 | LMNA (0.66) | CNR2LMNATSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL20847632 | 0.74 | HDAC8 (0.74) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL29952020 | 0.73 | CNR1 (0.61) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5510372 | 0.72 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL20393935 | 0.69 | MEN1 (0.69) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL20733373 | 0.69 | CA12 (0.58) | CNR2LMNAMEN1MAPTTSHR | |
| SCHEMBL19001352 | 0.69 | CA12 (0.64) | L3MBTL1LMNATSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL15798156 | 0.68 | CNR1 (0.70) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL20839243 | 0.68 | HDAC8 (0.65) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL15699683 | 0.68 | ALDH1A1 (0.53) | CNR2LMNATSHRALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10913710-B2 | Benzene disulfonamide for the treatment of cancer | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V (DE) | 2021-02-09 | — | — | US | disclosed |
| US-10913710-B2 | Benzene disulfonamide for the treatment of cancer | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V (DE) | 2021-02-09 | — | — | US | disclosed |
| EP-3351544-A1 | BENZENE DISULFONAMIDE FOR THE TREATMENT OF CANCER | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2018-07-25 | — | — | EP | disclosed |
| EP-3351544-A1 | BENZENE DISULFONAMIDE FOR THE TREATMENT OF CANCER | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2018-07-25 | — | — | EP | disclosed |
| WO-2018130625-A1 | BENZENE DISULFONAMIDE FOR THE TREATMENT OF CANCER | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2018-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913710-B2 | Benzene disulfonamide for the treatment of cancer | DUSP6, DUSP26, RASSF2 | PSEN1 3564/4885PSEN2 3493/4885APH1B 2111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.